Compare Tango Therapeutics Inc. (TNGX) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Tapestry, Inc. — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Tapestry, Inc. trades at $115.03 (market cap $22.87B). The key difference: Tapestry, Inc. is far larger — about 6.1× Tango Therapeutics Inc.'s market cap, and Tapestry, Inc. pays a 1.61% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Tapestry, Inc. for 70 Days on average.
| TNGX | TPR | |
|---|---|---|
Market Cap | $3.75B | $22.87B |
Volume | 9,619,106 | 1,963,570 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.90 | $164.78 |
52-Week Low | $7.50 | $98.81 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $2.77B | $25.67B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
TPR trades at $115.03, down 1.87% today, with a neutral technical signal and bearish moving averages. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined to $183M. Recent earnings beats and a $174.64 consensus price target suggest upside potential. International growth in China and Europe supports fiscal 2027 expansion plans.
Outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and 52% upside to price target. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation at 15.85 P/E. Strong cash flow generation and Coach brand momentum provide fundamental support despite recent price weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
